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The cornerstone of atrial fibrillation (AF) ablation is pulmonary vein isolation (PVI), which can be achieved in more than 95%
of patients at the end of the procedure. However, AF recurrence rates remain high and are related to recovery of PV conduction.
Adenosine testing is used to unmask dormant pulmonary vein conduction (DC). The aim of this study is to review the available
literature addressing the role of adenosine testing and determine the impact of ablation at sites of PV reconnection on freedom
from AF. Adenosine infusion, by restoring the excitability threshold, unmasks reversible injury that could lead to recovery of
PV conduction. The studies included in this review suggest that adenosine is useful to unmask nontransmural lesions at risk of
reconnection and that further ablation at sites of DC is associated with improvement in freedom from AF. Nevertheless it has been
demonstrated that adenosine is not able to predict all veins at risk of later reconnection, which means that veins without DC are
not necessarily at low risk. The role of the waiting period in the setting of adenosine testing has also been analyzed, suggesting that
in the acute phase adenosine use should be accompanied by enough waiting time.
1. Introduction
Catheter ablation is an effective treatment for atrial fibrilla-
tion (AF); the cornerstone of this procedure is durable and
effective pulmonary vein isolation (PVI). This is particularly
important for paroxysmal AF, whose pathophysiological
basis resides in the electrical properties of the strands of
muscular tissue that propagate from the left atrium (LA)
into the pulmonary veins [1]. These “transition” zones show
anisotropic conduction and can have altered excitability that
may be able to initiate AF. Following the recommendation of
the Heart Rhythm Society and the European Heart Rhythm
Association Guidelines in many centers, the first step of AF
ablation procedure is PVI, which can be achieved in more
than 95% of patients at the end of the procedure [2]. These
results are obtained with similar success rates with radiofre-
quency ablation (RF), cryoablation, and laser ablation [2].
However, AF recurrence rates remain high and substan-
tially unchanged in recent years [2]. AF recurrences are
related to recovery of PV-LA conduction; according to some
studies, in paroxysmal and persistent AF, the recovery of
the PV-LA conduction is associated with high recurrence
rates. Conversely, in paroxysmal AF patients, recurrences
are extremely rare in patients who maintain permanent PVI
[3, 4]. These concepts can be translated, at least partially, to
persistent AF, in which the importance of the recovery of the
PV-LA conduction has also been observed [3, 5].
It seems therefore essential to ensure, in the acute setting,
the effectiveness and durability of the PVI, as this has a direct
impact on the long-term outcome. When performing PVI,
two main issues have to be addressed: first, how to discern
whether permanent isolation (scar tissue) or a reversible
injury (oedema) has been obtained?; second, how to know
if acutely permanent isolation is going to predict absence of
reconnection in the long term?
More than ten years ago, the use of adenosine in PVI
was first described [6]. It was administered following initial
PVI to unmask dormant pulmonary vein conduction (DC),
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Figure 1: Microelectrode recordings before and after pulmonary vein isolation in a PV without dormant conduction (upper panel) and in
a PV with dormant conduction (lower panel). S: stimulus artifacts with no response. Dotted line: excitability threshold at −50mV (adapted
from Datino et al. [7]).
reversible injury, and identify vein reconnection. Adenosine
is now commonly used in clinical practice to assess DC with
the assumption that additional ablation at sites of reconnection
may improve long-term freedom from AF. The aim of this
paper is to review the available literature addressing the role
of adenosine testing and determine the impact of ablation at
sites of PV reconnection on freedom from AF following PVI.
2. Mechanism of Adenosine
First described by Arentz et al. in 2004 [6], the infusion of
adenosine after PVI was shown to be able to unmask incom-
plete lesions. After this observation, several studies found
similar results but it was only in 2010 that Datino et al. [7]
elegantly elucidated the mechanism of action of adenosine.
To understand adenosine’s action, it is necessary to review
the effect of RF energy on the LA myocardial cells (assuming
the same net effect for other energy sources). After RF
ablation, the cell membrane is damaged and is unable to
maintain the resting potential, which is the ability to hyperpo-
larize the cell membrane compared to the extracellular space.
This damage changes the resting potential to a level that is
above the excitability threshold, making the cell unable to
depolarize and conduct.
Potassium currents, activated during the recovery phase
of the action potential (AP), contribute to the membrane
hyperpolarization and are also damaged by RF lesions.
Transient outward potassium currents (IKado) are especially
present in PV cells and in the LA-PV junction.
Adenosine is able to increase these currents facilitating
the membrane hyperpolarization and restoring the excitabil-
ity threshold (Figure 1). Adenosine has a differential effect
on PV cells and LA cells. It is able to shorten the action
potential duration in both PV and LA cells but significantly
hyperpolarizes the resting membrane potential and increases
𝑑𝑉/𝑑𝑡max only in PV cells. After radiofrequency ablation,
if the membrane damage is not complete and permanent,
adenosine infusion can favour recovery of the resting poten-
tial and restore excitability. Those cells that have suffered
complete and irreversible damage will not be able to respond
to adenosine infusion and their membrane will remain
depolarized and unexcitable.
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Adenosine is also active on the Na channel of the PV
cells by removing the voltage-dependent 𝐼Na inactivation and
increasing the 𝑑𝑉/𝑑𝑡max (maximum velocity of phase 0 of
the AP). An interesting study by Cheung et al. [8] noted that
the PV reconnection occurs during the bradycardia phase
of adenosine infusion, confirming the hyperpolarization
mechanism underlying the adenosine effect.
The common final pathway of adenosine infusion is to
recover excitability and conduction capacity of those cells
with partial damage, thus unmasking reversible injury that
could lead to recovery of PV-LA conduction and favour AF
recurrences.
3. Studies Investigating the Use of
Adenosine in PVI
Eleven studies addressing the use of adenosine in radiofre-
quency PVI were identified (Table 1). In total, 3775 patients
were included in 4 retrospective studies (𝑛 = 845), 5
prospective nonrandomized studies (𝑛 = 283), and two
prospective randomized studies (𝑛 = 2650): the ADVICE
trial (Adenosine Following Pulmonary Vein Isolation to
Target Dormant Conduction Elimination, 𝑛 = 534) and the
UNDER-ATP trial (UNmasking Dormant Electrical Recon-
duction by Adenosine Triphosphate, 𝑛 = 2113), which will
be analyzed separately [9–11].
These studies have mainly followed two algorithms to
assess the utility of adenosine in PVI.
3.1. Adenosine Given versus Adenosine Not Given. Three ret-
rospective studies addressed the impact of adenosine admin-
istration after PVI on freedom from AF [12–14] (Table 1).
Each study compared a group of patients undergoing adeno-
sine infusion after PVI (and additional ablation in case of
DC) with a historical cohort from the same center of PVI
patients not receiving adenosine. These studies included 612
patients, 242 of whom received adenosine after PVI. PV
reconnection after adenosine infusion was observed in 190
PVs (31%) in 118 patients (49%).The time at which adenosine
was given was 20 minutes after PVI in 1 study [13] and
not specified in 2 studies [12, 14]. Additional ablation was
performed at sites of reconnection until complete isolation of
PVs after further adenosine testing. After an average follow-
up of 14months, cohorts of patients who had received routine
adenosine administration after PVI showed better outcome
with lower AF recurrence rate (Figure 2). The mean overall
freedom fromAF in patients given adenosine was 76% (73%–
80%) versus 61% (60%–62%) in patients not tested.
3.2. Reconnection and Reablation versus No Reconnection.
Seven studies, 5 prospective, involved 598 patients divided in
two cohorts: an adenosine infusion was used in all patients,
and those with DC were reablated until complete isolation
of PVs and were compared to patients without DC [6,
12, 15–19] (Table 1). In two studies (101 patients) reablation
was not performed in cases of reconnection [6, 16]. 452
patients had paroxysmal AF (76%). The timing of adenosine
administration was variable, ranging from immediately after
PVI to 30 minutes after PVI. In total, patients with DC after
adenosine testingwere 282 (47%) and out of 1569 veins tested,
23.7% demonstrated DC (1 study did not specify the total
number of veins tested [15]). After an average follow-up of
13 months, patients with DC and reablation did not show
better outcome in terms of freedom from AF, but in fact
they had an overall nonsignificant trend to worse outcome:
61% for patients with reconnection (38%–76%) and 71.5%
in cases with no DC (44%–89%) [20] (Figure 3). Excluding
those studies that did not perform further ablation in cases of
DC [6, 16], the same outcome was observed (61% versus 72%
AF freedom).
3.3. Interpretation of Study Results. Due to the many differ-
ences observed between these studies, it seems particularly
difficult to definitively interpret the results presented. Most
studies are retrospective with a historical cohort as the
comparator, which involves limitations related to the period
effect, the technological advances, and innovations. In addi-
tion, ablation techniques differ substantially between studies:
segmental PVI was the technique of choice in the earliest
studies while circumferential antral ablation or wide area
encirclement was mostly used in more recently published
ones.Thedifferences in ablation techniquesmay influence the
results in terms of AF recurrence and could introduce a bias
when evaluating the role of adenosine. In some studies, the
PVI was performed by antral ablation and electroanatomical
mapping followed by careful mapping of the DC sites after
adenosine administration [15, 18]. This technique allowed
accurate mapping of the earliest adenosine induced PV
activation and could help in guiding further ablation lesions.
In comparison with purely anatomical PV encirclement, this
electrophysiological approach may help in optimizing the
adenosine test, perhaps resulting in better outcome in terms
of AF recurrences.
Furthermore, adenosine dose and the presence of con-
current isoproterenol infusion show large variations across
the studies, and not all of them are specified which was
the endpoint of adenosine administration, with the presence
of temporary heart block as only a surrogate goal. Finally,
the wide range in timing of adenosine administration after
PVI could be an important issue when evaluating early
conduction recovery after ablation.
Despite these differences, the results seem to suggest
that the presence of dormant PV conduction revealed by
adenosine could be a marker for the absence of transmurality
of ablation encircling lesions in a vein at especially high
risk of reconnection. This could be secondary to anatomical
challenges or poor catheter contact and adenosine may help
to unmask the presence of ineffectively ablated areas [21].
In this setting, the use of the adenosine test, even if in
retrospective studies, has appeared to improve outcomes
compared to patients not tested.
On the other hand, it could be expected that further
ablation at sites of reconnection should lead to higher
freedom from AF recurrences but all studies analyzed failed
to demonstrate this assumption.
Generally, in the studies described, the additional abla-
tion is limited to the immediate site of PV reconnection
and no further extension of the waiting period or more
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Figure 2: Freedom from AF in three nonrandomized retrospective studies comparing adenosine given versus adenosine not given [12–14].
PVI: pulmonary vein isolation.
extensive reinforcement of the circumferential ablation line
was performed. So the overall picture is that it is important
to unmask veins at high risk but the usefulness of further
ablation is yet to be determined.
3.4.The ADVICE Trial. TheADVICE trial is first prospective
multicenter randomized study addressing the role of adeno-
sine in PVI [9, 10]. The aim of the study was to determine
whether an adenosine-guided ablation strategy improves the
long-term efficacy of PVI for the treatment of paroxysmal
AF. Of the 534 patients undergoing adenosine infusion, 284
(53%) had acute reconnection; 147 of them were randomized
to receive no further ablation while 137 received additional
RF pulses (over 95% success in eliminating DC). Out of the
250 patients without reconnection, 117 were randomized to
an intense follow-up registry.
It is important to note that all patients underwent a 20-
minute waiting period after PVI, and after that spontaneous
vein reconnection (27% of patients, 9% of PVs) was elimi-
nated and then adenosine was administered. Every vein was
tested separately by means of a circular catheter inserted into
the vein at the moment of the adenosine infusion, allowing
the exact localization of the reconnection point.
The primary endpoint was the first documented symp-
tomatic atrial tachyarrhythmia recurrence (AF, atrial flutter,
and atrial tachycardia) after the blanking period. After 12
months of follow-up, patients showing DC and receiving
additional ablation had a better outcome in terms of freedom
from atrial tachyarrhythmias (69.4%) than patients with DC
but without further ablation (42.3%, HR 0.44, 𝑝 < 0.001) and
also than those without reconnection (55.7%, HR 0.64, 𝑝 =
0.019) included in the intense follow-up registry (Figure 4).
Need for repeated ablation during follow-up was higher
in cases of acute reconnection without additional ablation
(35%) compared to patients undergoing further ablation
(20.4%, OR 0.48, 𝑝 = 0.006). The authors concluded that
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Figure 3: Freedom from AF in three nonrandomized studies comparing patients with adenosine induced reconnection and reablation
(dormant PV) versus no reconnection [15, 17, 18]. PV: pulmonary vein.
DC is associated with increased risk of atrial tachyarrhythmia
recurrence. Elimination of dormant pulmonary vein con-
duction reduces recurrent atrial tachyarrhythmias by >50%.
They consider that these results support the routine use of
adenosine for identification and elimination of DC during
PVI procedures for paroxysmal AF.
The ADVICE trial adds important information on the
role of adenosine infusion in PVI. On the one hand, it
shows that patients with DC not receiving further ablation
are extremely prone to AF recurrences. This result had been
suggested to a point by the nonrandomized studies involving
patients not tested with adenosine; the ADVICE trial con-
firms that speculation and shows the magnitude of the recur-
rence rate among those high risk patients. It clearly under-
lines the importance of looking for reconnection after an
appropriate waiting time. Furthermore by clearly separating
the effect of waiting time on spontaneous reconnection from
the adenosine administration, the studymay be able to evalu-
ate the net effect of adenosine testing on the presence of DC.
The second important finding of the ADVICE trial is
that further ablation of reconnected veins led to 12-month
freedom from symptomatic atrial tachyarrhythmia after a
single ablation procedure that was significantly higher than
that in patients with DC not reablated.This seems to indicate
that, after unmasking DC, it is useful to perform additional
ablation to improve long-term outcome.
The third group of patients, those without DC, were
intensively followed during 12 months and demonstrated
higher atrial tachyarrhythmia recurrence rates than patients
with DC and reablation. This finding may be considered
quite surprising as this group of patients could be classified
as being at low risk of vein reconnection, after a waiting
period, ablation of spontaneous reconnection, and negative
adenosine test.
As presented above, previous studies were unable to iden-
tify a benefit in further ablation, and on the contrary there
was a trend, although not significant, towards a higher rate of
recurrence compared to patients without reconnection.
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Figure 4: Freedom from symptomatic atrial tachyarrhythmia after a single ablation procedure in the ADVICE trial [9, 10].
Onemay speculate that negativity to adenosine test is not,
per se, an indicator of low risk of recurrence but instead a
response that leaves the door open to a possible reconnection,
perhaps occurring not so early. In fact adenosine response is
not an all-or-nothing phenomenon, but it is strictly related
to the degree of cell damage, and its ability to restore the
excitability threshold depends on the degree of depolarization
the cell has suffered. In view of these considerations, the
results of the ADVICE trial may suggest that patients without
adenosine unmasked DC should be checked very carefully
and perhaps, as discussed later, given more time during a
waiting period.
3.5. The UNDER-ATP Trial. The UNDER-ATP trial is a
recently published prospectivemulticenter randomized study
addressing the role of adenosine in PVI [11].
The aim of the study was to determine whether an
adenosine-guided ablation strategy improves the long-term
efficacy of PVI for the treatment of paroxysmal, persistent
(22.7%), and long lasting (10.1%) AF. Of the 2113 enrolled
patients, 1001 were randomized to standard PVI and sub-
sequent follow-up while 1112 underwent adenosine infusion
at a fixed dose of 0.4mg/Kg body weight after a variable
waiting time following PVI (median time 43min). After
waiting time, 42% of patients in both groups had sponta-
neous reconnection that was targeted with further ablation.
Thereafter, adenosine test was performed in the adenosine-
guided PVI group, unmasking dormant conduction in 489
PVs among 307 patients (27.6%). Additional RFwas delivered
until dormant conduction was completely eliminated (98%
of success). Almost 74% of patients were ablated with double
circular catheter technique; consequently, PVs were tested
with a single adenosine infusion for each pair of veins. A
considerable number of patients received additional lines,
specifically complex fractionated electrogram ablation (12%),
mitral isthmus line (6.7%), roof line (18.2%), and superior
vena cava isolation (13.9%).
The primary endpoint was recurrent atrial tachyarrhyth-
mias at 1 year with the blanking period of 90 days after PVI.
After 12 months of follow-up, no differences were
observed between groups, and 68.7% of patients in the
adenosine-guided PVI group and 67.1% of patients in the
conventional PVI group were free from the primary end-
point. Subgroup analysis showed no differences in terms
of primary endpoint between patients with paroxysmal AF
versus persistent/long standing and between patients with
PVI alone versus PVI + additional lines.
The results of this study are clearly divergent from those
obtained by the ADVICE trial. To understand these differ-
ences, it may be helpful to carefully analyze methodology
and treatment approach. The ADVICE trial allowed a fixed
waiting time of 20 minutes after completion of PVI and the
dose of adenosine used depended on the ability to produce
AV block or sinus pause. In the UNDER-ATP trial, the dose
of adenosine was predetermined and the same for every
patient, regardless of the effect produced.Moreover, therewas
no protocol regarding timing of adenosine administration,
which was infused after the left atrial ablation was complete,
resulting in a median time from PVI to adenosine more
than double that of the ADVICE trial. On this basis, it is
not surprising that in the UNDER-ATP trial the spontaneous
reconnectionwas higher and the adenosine induced dormant
conduction was lower than the ADVICE trial. Next, the
ADVICE trial examined only patients with paroxysmal AF
treated with PVI alone. In the UNDER-ATP trial, 32.8% of
the patients had persistent or long standing AF and PVI
procedurewas often accompanied by additional linear lesions
or complex electrogram ablation. This is remarkable since it
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is known that PVI in paroxysmal AF targets pulmonary vein
triggers and adenosine test may help in assuring complete
PVs isolation but it lacks any effect in case of additional
linear lesions or non-PVs triggers. Moreover, patients with
persistent or long standing AF develop more advanced
disease with other driving mechanisms that may increase the
risk of recurrence irrespective of the adenosine test results or
the PVs reconnection.
There is another aspect to consider when analyzing
the differences between the two studies. The UNDER-ATP
trial used an anatomical approach to PVI by extensively
encircling ipsilateral PVs mostly with the use of double
circular catheters. The double circular catheter was also used
for adenosine testing, preventing from accurate mapping of
the DC site and tagging of the reconnection points before
further RF delivery. Conversely, the ADVICE trial followed
a different approach, based on the EP mapping of the DC
sites for each vein that were tagged and targeted with further
ablation.
These considerations may help in understanding the
differences observed between both studies in order to extract
concepts that can be useful in clinical practice. It can be
suggested that adenosine test should probably be confined to
patients with paroxysmal AF treated with PVI alone and that
the accurate EP mapping of the DC site is a requisite for a
reliable adenosine test.
3.5.1. Other Energy Sources. The use of adenosine in PVI
has also been studied in cases of ablation with other energy
sources. Althoughwith less amount of evidence, cryoablation
and laser ablation already have some studies that have exam-
ined the role of adenosine (Table 2). There are 5 cryoablation
studies, 3 of themwith a control group [22–26], that analyzed
the presence of DC after adenosine infusion. In cases of
appearance of DC, additional applications were performed
by cryoballoon or with a conventional cryothermal catheter
until disappearance of DC after further adenosine infusion.
The lack of homogeneity between these studies, as seen for
RF ablation papers, prevents a reliable generalization of the
results. The differences in the methodology used, the limited
number of patients included, the presence of historical
cohorts as a comparator, the varying dose of adenosine,
and the presence or nonpresence of waiting time require
extremely careful interpretation of the results. The overall
picture is that the transmurality of the lesions is clearly related
to positivity to adenosine: these studies revealed that the
isolation of the veinswith the first freeze, the time to isolation,
and the nadir temperature are factors that identify veins
being permanently isolated and less prone to DC and long-
term recurrence. Two studies [23, 26] observed that freedom
from AF recurrences was higher in the adenosine and
reablation group compared to patients that did not receive
adenosine. In one study, it has been observed that ablation
with additional DC evaluation and treatment was found to
independently reduce the risk of AF recurrence at follow-up
[26]. Furthermore, the best results were obtained when the
waiting time was combined with adenosine infusion. Finally,
it can be noted (Table 2) that the percentage of patients with
DC (and therefore the percentage of veins) seems less in
cryoablation than in RF studies. The reason for this finding
is unclear; however, it has been suggested that one of the
strengths of cryoablation is the ability to create continuous
and contiguous injuries, whose absence could be related to
higher positivity to adenosine [29]. On the other hand, this
finding could be related to a different time dependency of
the adenosine response in cryoablation compared to RF, as
it could be suggested by the similar success rates of both
techniques in published studies in terms of freedom from
AF. Probably the different mechanism of lesion formation
implies a different time course of the adenosine response.
Nevertheless, the absence of direct comparison and the
paucity of evidence on this subject make every interpretation
merely speculative.
Regarding laser ablation, evidence about the use of
adenosine ismore limited; one study [27] compared cryoabla-
tion with laser ablation and found higher rates of DC in laser
ablation, but with the same AF recurrence rates after 1 year.
Another study [28] observed that DC is associated with poor
vein occlusion, longer duration of laser application, lower
mean power of the applied laser energy, and higher overall
number of 5.5W applications; targeting veins with dormant
conduction seems to improve rates of freedom from AF.
4. Waiting Time
Waiting time is a key variable when assessing PV recon-
nection after isolation. The mechanism of injury, based on
the cell membrane damage and subsequent death, suggests
that ensuring a permanent lesion requires some waiting time.
How much time should be waited after PVI is a matter of
discussion as there is a wide range of waiting times in the
studies analyzed, and in the daily setting it could be difficult
to allow more than 20 minutes after PVI. It has to be taken
into account that the waiting time alone has a very important
value because it allows those transient and nontransmural
injuries to recover and restore LA-PV conduction.
The recovery of conduction is greater when increasing the
waiting time and in some cases LA-PV conduction has been
observed 60minutes ormore after ablation [30]. Cheema and
colleagues [31] showed that patientswith 60minutes ofwaiting
time had reconnection in >30% of the PVs and such patients,
after additional ablation, had significantly higher freedom
from AF than patients without any waiting time after PVI.
Yamane and colleagues [32] combined the use of waiting
time and adenosine: the study algorithm had 3 subsequent
stages, each of them constituted by 30minutes of waiting time
and adenosine infusion (Figure 5(a)), followed by additional
ablation at each step in case of reconnection.They proved that
reconnection can be observed until 90 minutes after PVI and
after 2 separated adenosine administrations. Thanks to this
protocol, which obviously prolonged procedure times, they
obtained 92% of freedom from AF after 1 year. These studies
suggest that both waiting time and adenosine are useful when
assessing permanent lesions after PVI but it remains unclear
whether they provide the same information.
Jiang et al. [33] studied the relationship between wait-
ing time and adenosine: immediately after PVI adenosine
(20mg) was infused, a waiting period of 30 minutes was
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Figure 5: (a) Study algorithm and results from Yamane et al. [32]; PVAI: pulmonary vein isolation, ATP: Adenosine Triphosphate. (b)
Incidence of reconnection in individual pulmonary veins mediated by adenosine and/or time, adapted from Jiang et al. [33] (see text for
details).
allowed before assessment of reconnection (Figure 5(b)). Out
of 329 PVs, 80 presented reconnection: 15 were adenosine
positive but did not have permanent reconnection after the
waiting time, while, out of 65 time-positive reconnections,
32 were adenosine-negative. They also noted that most of
the PVs that reconnected with both adenosine-induction and
waiting time after 30󸀠 after PVI were found to be conducted
at the same gap. This study concluded that the agreement
between the two techniques is only moderate (𝐾 = 0.5) and
that adenosine infusion may facilitate the process of time
dependent reconnection.
In conclusion, it could be claimed that adenosine’s effect
may vary according to the degree of cell damage and mem-
brane depolarization. In case of greater damage, adenosine
may not be immediately able to restore the hyperpolarization
required to reach the excitability threshold and it may be
possible that only after enough waiting time its facilitating
action could lead to the recovery of the LA-PV conduction.
Therefore, the role of adenosine and waiting time can be
considered as interdependent and it is advisable to use both
techniques to ensure permanent injuries.
5. Prediction of Reconnection
As discussed above, adenosine seems quite useful to predict
acute reconnection and possibly additional ablationmay help
in reducing the risk of AF recurrence. Nevertheless, it has still
to be clarified if long-term PV reconnection, by far the most
important cause of AF recurrence after PVI, can be predicted
by adenosine induced dormant conduction.
Gula and coworkers [16] suggested that adenosine testing
for the assessment of transient conduction recovery does
not appear to predict recurrence of clinical AF. In 18 redo
procedures, they observed 31 reconnected veins: 9 had been
positive to adenosine and 22 negative at initial ablation. In
this study, adenosine correctly predicted 13 out of 36 veins,
resulting in positive predictive value (PPV) of 90% and
negative predictive value (NPV) of 15%.
Lin et al. [34] described similar results in their study
designed to address the ability ofDC to predict AF recurrence
and PV reconnection. In 26 redo procedures, they observed
53% rate of chronic PV reconnection (52 out of 99 PVs). DC
had a PPV of 82% and NPV of 51% (Figure 6(a)). In these
2 studies, adenosine was shown to have good specificity and
predictive value for future PV reconnection, especially if DC
was left unablated [16]. Sensitivity was low and adenosine was
unable to rule out chronic reconnection in case of absence of
DC.
These studies analyzed each vein as a whole and did
not focus on the precise spot of reconnection compared to
the spot of DC at initial ablation procedure. In order to
have reliable information about adenosine’s ability to predict
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Figure 6: (a) Adenosine testing results and PV reconnection rate at redo procedure in Lin et al. [34]. (b) Example of redo procedure
reconnection sites that totally differed from DC sites at first procedure [35]. DC: dormant conduction. PVI: pulmonary vein isolation (see
text for details).
outcome, it appears to be extremely important to understand
if a vein reconnects in the same spot with DC. Okishige
and coworkers [35] performed a prospective study to assess
the predictive value of the response to adenosine in terms
of identifying the reconnection sites associated with AF
recurrence. In their study, sites of DC were tagged using a
three-dimensional mapping system and left unablated. DC
was observed in 56 out of 91 patients (62%). After an average
follow-up of 15 months, 62 patients were free from AF
recurrences; 32 of them (52%) had DC during the first PVI.
A second ablation procedure was performed in 29 patients
(32%), all of them with DC during the first PVI.
Nineteen (66%) patients had reconnections sites that
all differed from those of the DC sites, whilst only 3
patients (10%) had all reconnections sites identical to the
DC sites. The remaining patients (24%) had reconnection
sites that involved not only DC sites but also different
sites (Figure 6(b)). The kappa test showed a poor agreement
between the DC sites and reconnection sites in all PVs
(𝜅 = 0.157). The overall result is that the vast majority of
the reconnection sites differed from the DC sites that were
detected by an adenosine injection in the first session. Finally,
the ADVICE trial showed that, in 110 redo procedures, the
reconnection rate was 48% for PVs with DC and reablation
(𝑛 = 40), 55% for PVs without DC (𝑛 = 229), and 88% for
PVs with DC without reablation (𝑛 = 82).
In conclusion, there seems to be enough evidence to
affirm that, despite a good specificity and PPV, the high num-
ber of false negative results (very low sensitivity) substantially
decreases the diagnostic capacity of adenosine in terms
of predicting long-term PV reconnection. These findings
strengthen the idea that the overall benefit of adenosine
testing and targeted ablation of DC is mostly related to the
elimination of those lesions that appear to be nontransmural
in the acute phase, with possible positive prognostic effect,
according to the ADVICE trial results. On the contrary, the
usefulness of the adenosine test as a predictor of chronic
reconnection is likely to be modest at best.
6. Other Techniques
New techniques have been described in order to improve
ability of identifying incomplete lesion after RF ablation.
Among new technologies, the use of Pace-capture PVI could
be useful in facilitating identification of residual gaps [36].
Andrade et al. compared 40 patients that received additional
ablation in case of atrial capture at high output pacing on the
ablation line with a group of patients with additional ablation
in case of adenosine revealed DC. Rates of pace capture in the
pace-capture group and rates of DC in the adenosine group
were found to be similar but patients in the pace-capture
group who underwent adenosine testing showed significant
reduction in the incidence of DC [37].
Recently the use of contact force catheters has been
introduced in RF ablation with the aim to obtain true
permanent lesions more efficaciously than standard catheters
[38]. It has been shown that the use of contact forces helps
in improving AF ablation effectiveness [39] and may lead
to better long-term results in terms of freedom from AF
[40]. One study evaluated adenosine response with the use
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of contact force catheters and observed that the presence of
DC is significantly reduced compared to standard catheters,
suggesting that this could be related to better AF freedom in
the long term [41].
7. Conclusion
This critical review tries to offer a complete overview on the
role of adenosine in PVI based on the available literature.
Data presented suggests that adenosine is useful to
unmask nontransmural lesions at high risk of reconnection.
This means that further ablation at sites of DC is associated
with improvement in freedom from AF after PVI. Therefore,
based on these considerations, adenosine should be used
routinely in clinical practice. Nevertheless, it is fundamental
to keep in mind the limitations of the adenosine testing. In
the acute phase, adenosine use should be accompanied by
enough waiting time, as the adenosine response immediately
after RF lesion may lack real value. Moreover, it has been
demonstrated that adenosine is not able to predict all veins
at risk of reconnection, mostly due to the very low negative
predictive value, which means that veins without DC are not
necessarily at low risk of reconnection.
Risks of PV reconnection and AF recurrence are related
to the ability of creating reliable permanent scar. Among
new technologies, contact force catheters improve lesion
transmurality and significantly reduce the incidence of DC.
In conclusion, the objective of PVI should be trying to
obtain complete and permanent lesions from the beginning,
and the combination of adenosine, waiting time, and contact
force assessment seems at the moment the best strategy to
achieve this goal.
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